推荐理由:FDA 对 RET 融合阳性实体瘤的儿童适应症给出传统批准,可了解该靶向药在儿科人群中的监管进展。
肿瘤
全部主题肿瘤领域的药物研发、临床数据、获批与治疗格局变化。
最新精选
第 981–1000 条 · 共 1,121 条
U.S. FDA@FDA精选AI 评分5858
Bristol Myers Squibb@bmsnews精选AI 评分5858百时美施贵宝(BMS)宣布在IMS26首次披露其针对特定成人多发性骨髓瘤患者治疗的III期试验结果。原文未给出具体药物名称、适应症细节及疗效数据。

推荐理由:BMS公布其多发性骨髓瘤疗法III期试验结果首次披露,可了解该疗法在特定成人患者中的关键数据。
FDA · 新闻稿精选AI 评分6262 FDA 批准 WELIREG 联合 LENVIMA 用于晚期 ccRCC
FDA 批准 WELIREG 联合 LENVIMA 用于晚期 ccRCC。该消息由 Eisai 发布,材料仅提供标题,未披露具体适应症细节与临床数据。
Merck@Merck精选AI 评分6262默沙东宣布与卫材合作的一款新联合治疗方案获FDA批准,用于部分晚期肾细胞癌患者。默沙东称这是肾癌治疗领域的重要进展,更多信息见其官网链接。

推荐理由:默沙东与卫材联合宣布FDA批准晚期肾细胞癌新联合治疗方案,读者可了解该适应症新增的治疗选项。
The Lancet精选AI 评分6060 ROAM/EORTC-1308 III期试验:WHO 2级非典型脑膜瘤完全切除后放疗与观察对比
ROAM/EORTC-1308 国际多中心、开放标签、III期随机对照试验比较了 WHO 2 级非典型脑膜瘤完全手术切除后辅助放疗与观察。研究结果提示,当患者更看重预防复发、而非放疗可能带来的迟发不良反应时,应考虑辅助放疗,这一做法可通过减少脑膜瘤复发使患者获益。具体决策应基于与患者的个体化讨论。
推荐理由:原文给出非典型脑膜瘤术后放疗与观察的头对头III期结论,读者可据此理解复发预防与放疗迟发不良反应之间的权衡。
FDA · 新闻稿精选AI 评分6262 FDA受理拜耳Lynkuet(elinzanetant)新适应症sNDA并授予优先审评
美国FDA已受理拜耳Lynkuet(elinzanetant)的补充新药上市申请(sNDA),并授予优先审评,拟用于治疗乳腺癌内分泌治疗相关的中重度血管舒缩症状。该消息由Business Wire发布。
推荐理由:FDA受理拜耳elinzanetant新适应症补充申请并授予优先审评,读者可了解该药在乳腺癌内分泌治疗相关血管舒缩症状上的监管进展。
MedCity News精选AI 评分6262 礼来支付1亿美元与诺诚健华达成多靶点药物研发合作
礼来将向北京诺诚健华支付1亿美元首付款及近期款项,启动一项多药物研发合作,针对最多5个未披露的靶点,诺诚健华将用其专有药物发现技术推进分子开发。若研发进展顺利,礼来还可能支付最高32.5亿美元的开发与商业里程碑款,诺诚健华另有资格获得获批产品销售的版税。诺诚健华专注肿瘤与自身免疫疾病药物,拥有ADC技术平台,目前在中国已有三款获批药物;礼来今年已宣布13项收购,并先后与信达生物、英矽智能达成合作。
推荐理由:礼来年内多次与中国药企达成研发合作,这笔交易的首付款与里程碑结构可供观察跨国药企在华早期管线布局。
NICE@NICEComms精选AI 评分5050NICE 已推荐 nirogacestat,为罕见硬纤维瘤患者提供 NHS 治疗选择,这是该机构针对这一非癌性病症推荐的首个靶向治疗。更多信息见 NICE 指南页面。
推荐理由:NICE 推荐 nirogacestat 用于罕见硬纤维瘤,读者可了解该靶向治疗在 NHS 体系中的准入定位。
Fierce Biotech精选AI 评分5555 复宏汉霖与Amberstone达成4.4亿美元T细胞衔接器交易
复宏汉霖(Henlius)与Amberstone达成一项价值4.4亿美元的T细胞衔接器(T-cell engager)交易。该交易的具体条款、涉及管线及金额构成尚未在现有材料中披露。
Fierce Biotech精选AI 评分6262 Grail 癌症血液检测通过 FDA 顾问委员会投票,等待 FDA 决定
Grail 的癌症血液检测通过了 FDA 顾问委员会投票,目前正等待 FDA 的最终决定。该投票是这款癌症血液检测在监管审评中的关键节点。
推荐理由:Grail 的癌症血液检测通过 FDA 顾问委员会投票,读者可了解该产品在监管审评中的关键节点。
FDA · 药品动态精选AI 评分6262 Elevar 的胆管癌药物 Lyrfigtu 获 FDA 批准,为韩国药企首次
Elevar 的胆管癌药物 Lyrfigtu 获得 FDA 批准,报道称这是韩国药企首次取得该资格。材料仅提供标题摘要,未披露适应症细节、临床数据或审批依据。
HUTCHMED@hutchmed精选AI 评分6060推荐理由:和黄医药在 ESMO26 公布赛沃替尼联合奥希替尼治疗 NSCLC 的两项 III 期研究数据,可了解该联合方案的最新临床进展。
FDA · 新闻稿精选AI 评分6262 FDA 顾问委员会关键投票支持 Grail 癌症检测的获益
据 reuters.com 报道,美国 FDA 顾问委员会在一项关键投票中支持 Grail 癌症检测的获益。该投票结果与这款癌症检测的监管审评相关。
推荐理由:FDA 顾问委员会就 Grail 癌症检测的获益投出关键票,读者可据此了解该产品审评进程的下一步走向。
Matthew Herper@matthewherper精选AI 评分6767引用Matthew Herper@matthewherperI'm live-tweeting the afternoon discussion of the FDA's advisory committee meeting on $GRAL's blood test to detect multiple types of cancer. This is a very interesting screening test. It definitely identifies cancers. But there are a good number of people who do not have cancer who will get a positive result, and a lot of patients who will get a negative result who do have cancer. One really big question is whether it's really right to say this test identifies cancer "early." And even tougher one is how to think about a test that might make patients skip existing screening tests -- that could mean, for instance, that more breast or colorectal cancers might be missed. The public hearing was very interesting. Some speakers, like Phil Castle from NCI, worried about the false negatives. There were also patients who felt they had been saved by the results of the test. I'll be threading my notes from the afternoon here. Forgive me for typos -- these things move fast.
推荐理由:FDA 专家委员会对 Galleri 多癌种筛查试验的三项投票结果,呈现了有效性与获益风险上的分歧。
Matthew Herper@matthewherper精选AI 评分6060记者 Matthew Herper 在 X 上直播 FDA 专家委员会对 $GRAL 多癌种血液检测的下午讨论。他指出该检测确实能识别癌症,但不少无癌症者会得到阳性结果,也有大量癌症患者得到阴性结果。
推荐理由:记者现场记录 FDA 专家委员会对一款多癌种血液检测的讨论,呈现假阳性、假阴性与是否影响现有筛查的争议。
HHS@HHSGov精选AI 评分5252引用U.S. FDA@FDAThe Trump administration is delivering on its promise: faster approvals, more cures, stronger American biotech. The FDA approved a treatment for pancreatic cancer months ahead of schedule — doubling survival vs. chemo. https://www.washingtonexaminer.com/op-eds/4733623/pancreatic-cancer-fda-approval-rasonque-daraxonrasib-trump/
MHRA (英国药监)精选AI 评分6262 MHRA 批准 lurbinectedin 联合阿替利珠单抗用于广泛期小细胞肺癌维持治疗
MHRA 于 2026 年 9 月 23 日批准 lurbinectedin(Zepzelca)与阿替利珠单抗联用,用于一线阿替利珠单抗、卡铂和依托泊苷诱导治疗后未进展的广泛期小细胞肺癌成人患者的维持治疗。
推荐理由:原文给出该药与阿替利珠单抗联用维持治疗的总生存期与无进展生存期数据,可据此判断其对广泛期小细胞肺癌二线维持治疗格局的影响。
Matthew Herper@matthewherper精选AI 评分6262引用Matthew Herper@matthewherperI’m following the FDA advisory committee on $GRAL’s Galleri blood test for detecting multiple types of cancer today and will be posting my thoughts here. So far, we’ve seen only company presentations, usually the dullest part of an advisory panel. But there have been some interesting tidbits. First, Grail is leaning heavily into simply the idea that they detect more cancers and can localize them, not getting into larger questions about the benefit to patients from doing so. See this slide. Speaking as part of Grail’s presentation, Mylynda Massart, a family medicine at UPMC, argued that the test can fit will with existing cancer screening and is something that many patients are eager to use. The panelists, in their first questions, expressed skepticism. One asked if the incredible, white-glove treatment that Grail gives doctors now can really scale. Another responded a Grail comment: “You’re carefully choosing your words. It is curative intent but you do not have outcome data.” Another panelist asked why the control arm of Grail’s randomized clinical trial in the UK was not included in the briefing document; the primary outcome of that trial was not included, either. Grail and FDA said that based on the agreement they came to with the FDA. Another panelist asked why so many patients from Grail’s other big study were not included in the briefing material; Grail said that had to do with when the data were submitted. What’s interesting is that the FDA seems to be telling the panel to limit the scope of its discussion. An FDA official said that both follow-ups and outcome data were beyond the scope of the claim being considered.
推荐理由:FDA 顾问委员会对 Galleri 多癌种血液检测的讨论,呈现审评中对结局数据与检测获益的分歧。
Matthew Herper@matthewherper精选AI 评分6262推荐理由:记录 FDA 专家委员会对 Galleri 多癌种早筛检测的现场质疑,呈现审评焦点与证据缺口。
NICE@NICEComms精选AI 评分5858
推荐理由:NICE 最终指南将 ibrutinib 联合 R-CHOP 列为干细胞移植的替代方案,读者可据此了解套细胞淋巴瘤一线治疗的支付与推荐路径变化。